P-630 Comparison of follitropin delta versus follitropin alfa in progestin-primed ovarian stimulation in IVF

Abstract Study question Is there a difference in clinical outcome between using follitropin delta and alfa undergoing progestin primed ovarian stimulation (PPOS) protocol? Summary answer There was no terms of pregnancy rates. What is known already Follitropin (REKOVELLE, Ferring Pharmaceuticals, Switzerland) the first recombinant human follicle-stimulating hormone (FSH) algorithm-based individualized dosing regimen while reducing risk hyperstimulation syndrome (OHSS) as compared with conventional strategies. The efficacy safety has been demonstrated randomized controlled trials (RCTs). design, size, duration We performed retrospective analysis 645 patients who underwent by PPOS protocol or April 2022 August 2022. (325 320 alfa, respectively.) Participants/materials, setting, methods 325 cycles women used were to alfa. following outcomes analysed; fertilized rate, 2 pronuclear embryo good quality blastocyst rate. A total 499 transfer cryo natural cycle replacement analysed about biochemical Main results role chance Baseline demographics for group were: age, 35.1±4.3 years 35.2±4.3 years; number previous IVF cycles, 1.6±1.6 1.7±1.7, respectively. laboratory data fertilization 81.4% 80.1%, 73.9% 71.5%, cleavage stage 59.4% 55.9%, 58.9% 55.7%, 41.3% 38.7%, Only rate significantly higher (P < 0.05) group. vitrified-warmed 257/325 (79.1%) 242/320 (75.6%) subsequent positive β-human chorionic gonadotropin (βhCG) reported 218/621 (35.1%) 194/570 (34.0%), Ongoing after 19.2% (n = 119) 19.6% 112) cumulative ongoing both 46.3%. Mild OHSS 131 (40.3%) 170 (53.1%), respectively 0.07). Limitations, reasons caution This non-controlled, study. Wider implications findings present study shows that addition risk, its individualised fixed-dose potential improve embryos although significant outcomes. Trial registration not applicable